APOE and Alzheimer disease: Phase II clinical trial on mild-to-moderate AD patientsDosage: 75 mg of bexarotene b.i.d., 150 mg after 1 weekPrimary endpoint:Change in brain amyloid burden measured by standard uptake unit regional (SUVr) according to genotypes involved in this trialSecondary endpoint:MMSEADAS-cogCDRNPIADCS-ADLSerum Aβ1-42 levelRatio of Aβ42 to Aβ40 in non-ApoE4 carriers